[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.146.141.60. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Other Articles
April 29, 1950

PLACENTAL TRANSFER OF CHLORAMPHENICOL (CHLOROMYCETIN®)

Author Affiliations

Denver

From the Department of Obstetrics and Gynecology and the Department of Biochemistry, University of Colorado Medical Center.

JAMA. 1950;142(17):1331-1332. doi:10.1001/jama.1950.02910350001001
Abstract

With the advent of chemotherapy and later the first of the antibiotics, it became possible to extend the range of treatment of the fetus via placental transfer from the maternal to the fetal circulation. This mode of treatment has been extensively used within the range of organisms affected and has proved highly effective both as a preventive and a curative treatment for the mother and fetus. When, in 1947, Ehrlich and associates succeeded in isolating and later producing synthetically pure crystalline chloramphenicol (chloromycetin®) treatment of another large group of infections was placed on a practical basis.1 The advantages of an orally effective antibiotic the scope of action of which includes most of the infectious agents encountered in obstetric practice, from which no toxic reactions have been reported and which has the potentiality of an inexpensive product are many. The purpose of this study was to determine, if possible, whether

First Page Preview View Large
First page PDF preview
First page PDF preview
×